Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Phase 1 trial of a novel MAPK pathway inhibitor in advanced solid tumors; registry record with no results posted, only planned endpoints for safety, dosing, and antitumor activity assessment.
This is a Phase 1 safety and pharmacokinetics study registration with no results posted; it describes planned enrollment and design only, typical of early-stage clinical development.
This is an active registry record for an ongoing interventional study with no results posted; it describes a planned behavioral intervention in a specific population without efficacy data.
Phase 2 interventional trial in an active but unrecruitment stage with no results reported in this registry record; design and endpoints are specified but outcome data are absent.
Phase 1 dose-escalation trial of a novel bispecific antibody in solid tumors; designed to establish safety and tolerability with preliminary efficacy assessment, not yet recruiting and results not reported.